[68Ga]Ga-DOTA标记生长抑素类似物PET/MRI检测神经内分泌肿瘤患者肝转移的诊断价值:系统评价与Meta分析
该系统评价与Meta分析纳入6项研究共638个肝转移灶,比较[68Ga]Ga-DOTA-SSA PET/MRI与PET/CT对神经内分泌肿瘤肝转移的检出率。PET/MRI合并检出率为93.5%,PET/CT为76.8%,PET/MRI显著更高(p=0.02),附加价值为15.3%。作者认为PET/MRI整体表现良好,但因纳入研究少,需进一步研究验证其临床实用性。
要点
- PET/MRI对NET肝转移的合并检出率为93.5%,高于PET/CT的76.8%(p=0.02)。
- PET/MRI较PET/CT的附加价值为15.3%(95%CI 8.0-27.4%)。
- 研究地点和预设影像诊断标准的使用与PET/MRI研究间异质性相关。
核心结论
- [68Ga]Ga-DOTA-SSA PET/MRI对NET患者肝转移检测整体表现良好,但因符合条件的硏究数量少,需进一步研究验证其临床实用性。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE、EMBASE和Cochrane数据库,纳入6项原始研究(638个肝转移灶),采用随机效应模型限制性最大似然估计计算并比较PET/MRI与PET/CT的合并检出率。
诊断标准与关键数值
- PET/MRI对肝转移的合并检出率为93.5%(95%CI 85.1-97.3%;I²=84.8%),PET/CT为76.8%(95%CI 64.8-85.6%;I²=87.8%),PET/MRI显著更高(p=0.02),附加价值为15.3%(95%CI 8.0-27.4%)。敏感性分析后PET/MRI检出率为94.8%(95%CI 90.8-97.2%;I²=42.1%),PET/CT为80.0%(95%CI 65.3-89.5%;I²=90.0%)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 纳入的合格研究数量少,需进一步研究验证[68Ga]Ga-DOTA-SSA PET/MRI的临床实用性。
- PET/MRI检出率存在研究间异质性(I²=84.8%),敏感性分析后I²=42.1%。
- PET/CT检出率存在研究间异质性(I²=87.8%),敏感性分析后I²=90.0%。
- 研究地点和预设肝转移影像诊断标准的使用与PET/MRI研究异质性相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the diagnostic value of [68 Ga]Ga-DOTA-labeled-somatostatin analogue ([68 Ga]Ga-DOTA-SSA) PET/MRI for detecting liver metastasis in patients with neuroendocrine tumor (NET) and to compare it with [68 Ga]Ga-DOTA-SSA PET/CT.
METHODS: A search of MEDLINE, EMBASE, and Cochrane was performed to identify original articles reporting the detection rate of [68 Ga]Ga-DOTA-SSA PET/MRI for liver metastasis in comparison with PET/CT. The pooled detection rates for liver metastasis on PET/MRI and PET/CT were calculated and compared using a restricted maximum likelihood estimation of random-effects model. The pooled added value of PET/MRI in comparison with PET/CT was calculated. Sensitivity analysis and subgroup analysis were performed to explore causes of study heterogeneity.
RESULTS: In the six included studies (638 liver metastases), the pooled detection rates for liver metastasis on [68 Ga]Ga-DOTA-SSA PET/MRI and PET/CT were 93.5% (95% confidence interval [CI], 85.1-97.3%; I2 = 84.8%) and 76.8% (95% CI, 64.8-85.6%; I2 = 87.8%), respectively. PET/MRI had a significantly higher detection rate than PET/CT (p = 0.02), with 15.3% (95% CI, 8.0-27.4%) added value over PET/CT. After sensitivity analysis, the recalculated detection rates for liver metastasis were 94.8% (95% CI, 90.8-97.2%; I2 = 42.1%) for PET/MRI and 80.0% (95% CI, 65.3-89.5%; I2 = 90.0%) for PET/CT. The study location and the use of predefined imaging criteria for liver metastasis were associated with PET/MRI study heterogeneity.
CONCLUSION: [68 Ga]Ga-DOTA-SSA PET/MRI had good overall performance for detecting liver metastasis in patients with NET. Because of the small number of eligible studies, further studies are needed to validate the clinical usefulness of [68 Ga]Ga-DOTA-SSA PET/MRI.
KEY POINTS: • [68 Ga]Ga-DOTA-SSA PET/MRI had a higher pooled detection rate for liver metastasis than PET/CT (93.5% vs. 76.8%). • The added value of [68 Ga]Ga-DOTA-SSA PET/MRI for detecting liver metastasis in comparison with PET/CT was 15.3%. •Study location and the predefined imaging criteria for liver metastasis were significant factors causing PET/MRI study heterogeneity.
引用
- Choi SJ, Choi SH, Lee DY, et al. Diagnostic value of [68 Ga]Ga-DOTA-labeled-somatostatin analogue PET/MRI for detecting liver metastasis in patients with neuroendocrine tumors: a systematic review and meta-analysis. Eur Radiol. 2022. PMID: 35092473. doi:10.1007/s00330-021-08527-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。